Adèle Coriati1, Sophie Ziai1, Mirna Azar2, Yves Berthiaume3, Rémi Rabasa-Lhoret4. 1. Institut de Recherches Cliniques de Montréal, Montréal, Québec H2W 1R7, Canada; Department of Nutrition, Université de Montréal, Montréal, Québec H3T 1A8, Canada. 2. Department of Medicine, Université de Montréal, Montréal, Québec H3T1J4, Canada. 3. Institut de Recherches Cliniques de Montréal, Montréal, Québec H2W 1R7, Canada; Cystic Fibrosis Clinic of the Centre hospitalier de l'Université de Montréal, Montréal, Québec H2W 1T8, Canada; Department of Medicine, Université de Montréal, Montréal, Québec H3T1J4, Canada. 4. Institut de Recherches Cliniques de Montréal, Montréal, Québec H2W 1R7, Canada; Department of Nutrition, Université de Montréal, Montréal, Québec H3T 1A8, Canada; Cystic Fibrosis Clinic of the Centre hospitalier de l'Université de Montréal, Montréal, Québec H2W 1T8, Canada; Department of Medicine, Université de Montréal, Montréal, Québec H3T1J4, Canada. Electronic address: remi.rabasa-lhoret@ircm.qc.ca.
Abstract
BACKGROUND: CFRD is preceded and associated with a significantly increased morbidity and mortality. We aimed to characterize a large newly established glucose tolerance subgroup named INDET (indeterminate; 1-h oral glucose tolerance test (OGTT)>11.0 but 2h-OGTT<7.8 mmol/L) in adult patients with cystic fibrosis (CF). METHODS: All CF participants (n=252, ≥18 yrs without CFRD) underwent a 2h-OGTT with glucose and insulin sample measurements every 30 min. They were then classified as having either normal, impaired, or INDET glucose tolerance, or de novo CFRD. Other clinical characteristics were collected such as the BMI and pulmonary function. RESULTS: All groups were of similar age (P=0.629) and BMI (P=0.813). We found that the INDETs displayed decreased lung function comparable to de novo CFRD. OGTT-derived glucose or insulin secretion/sensitivity parameters cannot fully explain this observation. CONCLUSIONS: Prospective studies are required to establish if the INDET-CF group can identify clinically relevant outcomes.
BACKGROUND: CFRD is preceded and associated with a significantly increased morbidity and mortality. We aimed to characterize a large newly established glucose tolerance subgroup named INDET (indeterminate; 1-h oral glucose tolerance test (OGTT)>11.0 but 2h-OGTT<7.8 mmol/L) in adult patients with cystic fibrosis (CF). METHODS: All CF participants (n=252, ≥18 yrs without CFRD) underwent a 2h-OGTT with glucose and insulin sample measurements every 30 min. They were then classified as having either normal, impaired, or INDETglucose tolerance, or de novo CFRD. Other clinical characteristics were collected such as the BMI and pulmonary function. RESULTS: All groups were of similar age (P=0.629) and BMI (P=0.813). We found that the INDETs displayed decreased lung function comparable to de novo CFRD. OGTT-derived glucose or insulin secretion/sensitivity parameters cannot fully explain this observation. CONCLUSIONS: Prospective studies are required to establish if the INDET-CF group can identify clinically relevant outcomes.